X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxprenolol
Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-002
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Faraday Pharmaceuticals
Deal Size: $134.7 million Upfront Cash: $2.7 million
Deal Type: Licensing Agreement April 13, 2021
Details:
Faraday gains global rights to develop and commercialize S-oxprenolol for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxprenolol
Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-002
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
ACM-002 (S-oxprenolol) is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed. The new patent contains claims which cover the treatment of the symptoms of cachexia in patients having a late stage cancer.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
